Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Toucan Capital Corp.

Toucan Capital Fund II, L.P. is a $120 million venture capital fund (SBIC) focused on seed and early-stage life science and advanced technology investments. Toucan Capital Corp. launched its first fund in 1997 and began investing its current fund in August of 2001. Toucan invests nationwide and is one of the largest and most active venture capital funds in seed and early-stage life science. Toucan has also been an early investor in nanotechnology. Toucan is especially active in the mid-Atlantic region, one of the richest markets in the country for life science and certain advanced technologies, and a market that has generally been underserved by venture capital.
Toucan usually serves as the lead or co-lead investor and takes an active, hands-on role working closely with company management to help build its portfolio companies. For example, Toucan often assists its portfolio companies in building and strengthening their intellectual property base, formulating partnering and regulatory strategies, and ensuring that commercialization and payment/reimbursement issues are addressed from the earliest stages of the company's development.


Contact Details:
7600 Wisconsin Avenue 7th Floor
Bethesda
Maryland
20814
United States of America
Tel:(240) 497-4060
Fax:(240) 497-4065
Email:info@toucancapital.com
WWW:

www.toucancapital.com/




Loading...

Recent Publications by Toucan Capital Corp.:

Current status of clinical trials for glioblastoma.
Glioblastoma, the most highly aggressive and lethal form of brain cancer,...
11th June, 2008
Toucan Capital Corp, Rev Recent Clin Trials. 2006 Sep;1(3):265-81.
Technology evaluation: bevacizumab, Genentech/Roche.
Bevacizumab, an antivascular endothelial growth factor monoclonal...
9th April, 2004
Toucan Capital Corp, 7600 Wisconsin Ave, 7th Floor, Bethesda, MD 20814, Curr Opin Mol Ther. 2003 Dec;5(6):657-67.

BioNews Results for Toucan Capital Corp.:

News and FDA Updates for Celgene (NASDAQ:CELG), Genzyme (Nasdaq:GENZ)
American Chronicle:  Nov 16 2009 12:51AM Matching: capital corp
Our Members Know First!! PSGI-'Prime Star Group Introduces Delizia Limited Cigars' Sign Up Today!!
Pharmacy Choice:  Nov 14 2009 12:56AM Matching: capital corp
Financial & Company Analysis on MMM, BEAV, ACAS, XOMA, CEDC and A...
Zibb:  Nov 13 2009 12:59PM Matching: capital corp
Girard Gibbs LLP Announces Class Action Lawsuit Filed on Behalf of Investors Who Purchased Medical Capital Not
Genetic Engineering News:  Nov 13 2009 9:56PM Matching: capital corp
Elan to Present at Lazard Capital Markets Annual Healthcare Conference07000000
TradingMarkets:  Nov 13 2009 5:39AM Matching: capital corp
Promote your company here: BioNewsCast - Press Release Distribution

View more Toucan Capital Corp. news.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 427 times since April 2007, the link to the organisation's website has been followed 73 times

Recent Search Terms used to find this page: toucan capital | toucan capital | TOUCAN clinical trial | TOUCAN clinical trial | Toucan Capital Fund II lp | what is the affect it growth development of the toucan | toucan capital | Toucan Capital | toucan venture capital press release | .

Search for more companies in Bethesda

Search for more companies in Maryland



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Toucan Capital Corp.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.